

GENERAL INDEX

(A - Abstract, E - Editorial, L - Letter to the Editor)

- Abdominal pseudolymphoma, mixed connective tissue disease, Sjögren's syndrome and, 70
- Abnormal bowel permeability in arthritis—relationship to disease activity and spondylitis, 70
- Abstracts of BSR 1st AGM, 74-112
- Abstracts of BSR Provincial Meeting 1985, 197-222
- 'Acute arthritis clinic'—one year's experience, 210
- Acute-phase proteins, 94
- Adsorption of IL1 and β -glucuronidase by crystals, 200
- Aetiopathogenesis of inflammatory joint disease, 222
- Aggregate binding factor in cartilage, 97
- AL-ASZAWI, AJ, *see* Al-Rawi ZS.
- AL-CHALABI T, *see* Al-Rawi ZS.
- Alcohol consumption in Dupuytren's contracture, 220
- AL-DUAI A, *see* Edwards JCV.
- Algodystrophy: assessment by thermography and response to therapy with pulsed electromagnetic fields, 85
- AL-HUSSAINI AS, SWANNELL AJ. Peripheral joint involvement in polymyalgia rheumatica: a clinical study of 56 cases, 27
- ALLEN BR, *see* Jenkins JS.
- ALLEN JG, *see* Bird HA.
- AL-RAWI ZS, AL-ASZAWI AJ, AL-CHALABI T. Joint mobility among University students in Iraq, 326
- AMENTO EP, *see* Bhalla AK.
- AMOR B, *see* Kahan A.
- AMOS N, *see* O'Sullivan M.
- 'Analgesic hip', reappraisal of, 91
- Angiogenesis, induction of by macrophages, 76
- Angiogenic factor, lymphocyte, 203
- Angiotensin-converting enzyme in polyarthritis, 201
- Anglo-US Fellowships, 5
- Ankylosing spondylitis
- and Klinefelter's syndrome: does the X-chromosome modify disease expression? 277
 - bowel permeability in, 77
 - cytotoxicity of anti-Klebsiella serum for lymphocytes of patients, 216
 - defective immunity to EBV in, 87
 - destructive spinal lesions: of, 221
 - diagnostic criteria for, evaluation, 242
 - synovial membrane in, immunohistological analysis of, 80
- ANSELL BM, *see* Williams PL.
- Anterior uveitis, HLA-B27+, phagocytic response of patients, 332
- Antibodies
- anticentromere in patients with chronic rheumatic diseases, 75
 - antipeptidoglycan, 198
 - antiphospholipid, 75, 78
 - monoclonal,
 - demonstrating granulocytes, 79
 - from patients with RA, 111
 - used in identification of La antigen components, 100
 - serum, to
 - bovine antigens in adult RA, 78
 - extractable nuclear antigens, patient characteristics, 207
 - to alanyl-tRNA synthetase and transfer RNA, 101
 - to CMV and EBV in SS and RA, 88
- Antibody-antigen complexes and RF, 83
- Antibody, antihistone, specificity patterns, 99
- Antibody responses, systemic, rheumatoid synovial membranes participate in, 74
- Anticentromere antibodies in patients with chronic rheumatic diseases: preliminary studies and characterization of antigens, 75
- Anti-DNA antibody idiotype, 100
- Anti-DNA in SLE, complement fixation by, 83
- Antigen-antibody complexes and RF, 83
- Antigen binding sites of anti-La antibodies, distinct idiotype in, 99
- Antigenic determinant of rheumatoid factor, 86
- Antigens, bacterial, in B27-associated arthropathies, 106, 227
- Antihistone antibody specificity patterns, 99
- Anti-La antibodies, 99
- Antimalarial drugs, biochemical studies, 206
- Antinuclear antibodies in the families of patients with SS, 212
- Antiphospholipid antibodies, 75, 78
- Antirheumatic drugs
- in pregnancy and lactation, 230
 - new, screening for, 381
- Antirheumatic medication
- during lactation, 291
 - in pregnancy, 282, 382
- Antirheumatoid drugs, disease-modifying, 167
- ARCHER JR, STUBBS MM, GECZY AF. Cytotoxicity of anti-Klebsiella serum for lymphocytes of ankylosing spondylitis patients from London (A), 216
- ARCHER JR, *see also* Haskard DO; Kirk AP.
- AREND WP, JOSLIN FG, MASSONI RJ. Characteristics of IL1 production by human monocytes (A), 107
- ARMSTRONG RD, KAY A, GIBSON T, COLLIER L, HORROCKS A. Flexor tenosynovitis in RA—effect of local steroid injections (L), 225
- ARMSTRONG RD, MACFARLANE DG, PANAYI GS. Ankylosing spondylitis and Klinefelter's syndrome: does the X chromosome modify disease expression? 277
- Arthritis, *see also* Rheumatoid arthritis
- abnormal bowel permeability in, 77
 - acute, clinic—one year's experience, 210
 - and purpura, femoral mycotic aneurism presenting as, 364
 - Brucella, synovia rupture complicating, 191
 - copper, iron, free radicals and, 123
 - haemophilic, joint scans in, 263
 - induced by human Parvovirus infection, 74
 - of unknown cause, synovial biopsy in, 232
 - pain, nature of, 53
 - reactive,
 - comparison of outbreak and sporadic cases, 112
 - due to *Salm. schwarzengrund* in a patient with asymptomatic spondylitis, 194
 - septic, 197
- Arthroplasty, Gerard cup, in inflammatory arthropathy of the hip, 199
- Asacol in RA, 226
- ASHERSON, RA, *see* Evans HB; Harris EN; Kennedy HG.
- ASPDEN RM, YARKER YE, HUKINS DWL. Structure, function and failure of the meniscus of the knee joint
- Association between cheiroarthropathy and frozen shoulder in patients with insulin-dependent diabetes mellitus (A), 76
- ASTBURY C, *see* Bird HA.
- Asthma, effects of corticosteroid on bone mass in patients, 215
- ATKINS E. Fever: historical perspectives and evolution of modern views (A), 93

GENERAL INDEX

- Auto-antibodies,
lymphocytic in RA, 104
PMN cell directed in Felty's syndrome, 84
- Autoimmune disease,
digital gangrene in, 220
interferon-induced enzyme in, 89
radiosensitivity of peripheral blood lymphocytes in, 87
- AVIRAM M, *see* Lorber M.
- B27-associated arthropathies, lymphocyte proliferative responses to bacterial antigens in, 11, 106, 227
- B-cell colony stimulating activity in RA synovial fluids, 206
- BACON PA. Evolving concepts in rheumatology: seminar report, 300; *see also* Coppock JS; Farr M; Grindulis KA; Morris C; Salmon M; Scott DL; Struthers GR; Symmons DPM.
- Bacterial antigens in B27-associated arthropathies, 11
- BADLEY EM. Evaluating the consequences of new consultant appointments in rheumatology in the North Western region (A), 210
- BAIG F BEGUM, *see* Bourne JT.
- BARNES CG, *see* Thompson PW.
- BARNES L, *see* FitzGerald OM.
- BARNES RMR, *see* Hopkins DFC.
- BARR W, *see* Rajan KT.
- BARRY C, *see* FitzGerald OM.
- Behçet's syndrome with myositis and glomerulonephritis, 372
- BEHN A, *see* Cramb R.
- BELCH JFF, MADHOK R, MCARDLE B, CAPELL H, FORBES C, STURROCK RD. Stanozolol as a treatment for RA (A), 102
- BELCH JFF, O'DOWD A, CAPELL H, STURROCK RD. Platelet sensitivity to a prostacyclin (PGI₂) analogue in SS (A), 91
- BELCH JFF, O'DOWD A, FORBES CD, STURROCK RD. Platelet sensitivity to a prostacyclin analogue in SS, 346
- BELL AL, *see* Hurst NP.
- BENNETT D. Some characteristics of naturally-occurring RA in the dog (A), 198
- Benoxaprofen: a potent inhibitor of monocyte-endothelial cell interaction, 84
- BERKHOUT B, MACFARLANE JD, CATS A. Symptomatic osteoarthritis of the knee, 40
- BERNSTEIN RM, BUNN CC, MATHEWS MB. Myositis sera with separate antibodies to alanyl-tRNA synthetase and transfer RNA (A), 101
- BERNSTEIN RM, HOBBS RN, LEA DJ, WARD DJ, HUGHES GRV. Patterns of antihistone antibody specificity in systemic rheumatic disease (A), 99
- BERRY H, *see* Kirk AP.
- BHALLA AK, AMENTO EP, KRANE SM. An enhancement of IL1 production from monocytes by 1,25-dihydroxy-vitamin D₃ (A), 108; 1,25-dihydroxyvitamin D₃ inhibits lymphocyte proliferation and IL2 production: a potential new immunosuppressant (A), 110
- BHOJAL BS, *see* Isenberg DA.
- BINDER AI, PAICE EW, WHITE AG. Corticosteroid prescribing in RA (L), 380
- BINDER AI, PARR G, HAZLEMAN B. A controlled study of oral prednisolone in frozen shoulder (A), 215
- Biofeedback, hypnosis and relaxation training in chronic pain (A), 213
- BIRD HA, ALLEN JG, DIXON JS, WRIGHT V. A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid, 351
- BIRD HA, HOPKINS R, HILL J, SURRELL K, ASTBURY C, MILLER A, WRIGHT V. A double-blind controlled trial of etretinate and ibuprofen in psoriatic arthritis (A), 102
- BIRD HA, *see also* Dixon JS.
- BIARNASON I, *see* Williams PL.
- BLACK CM, WELSH KI, LAURENT R. The susceptibility to and progression of vinyl chloride disease (A), 96
- BLACK CM, *see also* Pereira RS.
- BLAGRAVE P, *see* Gibson T.
- BLAKE DR, LUNEC J. Copper, iron, free radicals and arthritis (E), 123
- BLAKE DR, LUNEC J, MORRIS C, HEWITT S. Desferrioxamine treatment for rheumatoid synovitis (A), 214
- BLAKE DR, *see also* Brailsford S; Morris CJ.
- BLANN AD, *see* Symmons DPM.
- Bleeding disorders of childhood, musculoskeletal problems in, 221
- BLOWERS LE, JAYSON MIV, JASANI MK. Control of protein synthesis by dexamethasone in human polymorphonuclear leucocytes (A), 78
- BOURNE JT, SHINE B, BAIG F BEGUM, DOYLE DV. C-reactive protein in synovial fluid and serum (A), 203
- Bowel permeability, abnormal, in arthritis, 77
- BOYD M, *see* Fay A.
- BRAILSFORD S, BLAKE D, LUNEC J, GILBEY S, WINYARD P. Synovial macrophage dysfunction in RA (A), 80
- BRADLOW A, MOWAT AG. Comparison of reconstructive orthopaedic surgery in patients with seropositive and seronegative RA, 179; Dupuytren's contracture and alcohol (A), 220
- BRADLOW A, SMITH R. Myositis (fibrodysplasia) ossificans progressiva: diagnosis, natural history and treatment in 22 cases (A), 200
- BRANDMAN S, VANDENBURG MJ, JENKINS R, CURRIE WJC. The effect of nonsteroidal anti-inflammatory therapy on plasma neuropeptide concentrations in patients with OA, 46
- BRANDT K, PALMOSKI MJ. Rapid reversibility of changes in articular cartilage induced by compressive stress (A), 98
- BREEDVELD FC, DOEKES G, CLAAS FHI, LAFEVER GJM, CATS A. Re-evaluation of PMN directed auto-antibodies in patients with Felty's syndrome (A), 84
- BRERETON JD, *see* Gardner DL.
- BRESNIHAN B. Collagen immunity: seminar report, 298; *see also* FitzGerald O; Hanly J; Mongey A-B.
- BREWERTON DA, *see* Dixey JJ.
- BRIDTS CH, *see* De Clerck LS.
- BRIGGS D, *see* Pereira RS; *see also* Puttick AH.
- BRIGHTON SW, DE LA HARPE AL, VAN STADEN DA. The prevalence of OA in a rural African community, 321
- British Society for Rheumatology: Seminar reports, 298
- BRODERICK A, *see* Farr M.
- BROOK JG, *see* Lorber M.
- BROOKS P, NEEDS C. Antirheumatic medication in pregnancy (L), 382
- BROOKS PM, *see* Needs CJ; Smith MD.
- BROUGHTON RBK, *see* Rajan KT.
- BROWN DH, *see* Pullar T.
- BROWN KA, CHASTY RC, SHEEHAN NJ, YATES DAH, KIRK AP, PERRY JD, MCCARTHY D, DUMONDE DC. The interaction of rheumatoid PMN with cultured endothelium (A), 84
- BROWN KA, FERRIE J, WILBOURN B, DUMONDE DC. Benoxaprofen: a potent inhibitor of monocyte-endothelial cell interaction (A), 84

GENERAL INDEX

- BROWN KA, SIMMONS K, KIRK AP, PERRY JD, DUMONDE DC. Enhanced chemotaxis of monocytes in RA (A), 83
- BROWN MR. Corticosteroid treatment in RA (L), 380
- BROWN N, *see* Reid DM.
- BROWN T, *see* Reid DM.
- Brucella arthritis, synovial rupture complicating, 191
- BUCKTON JB, *see* Doble ATA.
- BUNN CC, *see* Bernstein RM; Mackworth-Young CG.
- BURDEN T, *see* Cashin CH.
- BURKE M, *see* Thompson RN.
- BURTON AK. Scientific research in osteopathy (E), 2
- BYRON MA, CHAPEL HM, LEDINGHAM JGG, MOWAT AG. SLE in a District General Hospital (A), 208
- BYRON MA, MOWAT AG. Corticosteroid prescribing in RA—the fiction and the fact, 164
- BYWATERS E. The value of synovial biopsy (E), 229
- CALDER V, *see* Parker JD.
- CALIN A. Lymphocyte proliferative responses to bacterial antigens in B27-associated arthropathies (L), 227
- CALLAN, A, *see* FitzGerald O.
- CAMBRIDGE G, FAITH A, SNAITH ML. Lymphocyte proliferative responses to purified human skeletal muscle membranes (A), 74
- CAMPBELL AJ, FERRY DG, EDWARDS IR. Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects, 176
- CAPELL H, HUNTER JA. Corticosteroid treatment in RA (L), 379
- CAPELL HA, *see* Belch JFF; Parker JD; Pullar T.
- CARTER SD, HUTTON CW, DIEPPE PA. Adsorption of IL1 and β -glucuronidase by crystals (A), 200
- CARTER SD, MAHK SR, PONSFORD FM, ELSON CJ. Synovial fluid IgG as antigen for IgM RF (A), 203
- Cartilage
an aggregate binding factor in, 97
articular
human, long-term culture, 218
reversibility of changes induced by compressive stress, 98
role of proteoglycan and collagen in, 200
stiffness of, in early stages of OA, 219
degradation of, in contact with soft tissue, 98
of human femoral condyle, proteoglycan synthesis in, 219
- Cartilages, sacral and iliac in man, 90
- CASBURN-BUDD R, *see* Jones MG.
- Case against 'seronegative RA': a laboratory viewpoint, 225
- CASEY E, *see* Hanley T.
- CASHIN CH, LEWIS EJ, BURDEN T. The development of screening tests for D-penicillamine-like activity based on *in vivo* interactions with copper, 137
- CASHIN CH, *see also* Roberts NA.
- CATS A, *see* Berkhout B; Breedveld FC; De Clerck LS; The HSG.
- CRAWLEY MID, *see* Cooper C; Walters MT.
- CAWSTON T, *see* Mercer E; Smith AJ; Wright JK.
- CAYLEY J, *see* Hylton W.
- CELINSKA E, *see* Griffin J.
- Cellular immune defect of rheumatoid arthritis: the role of HLA status and the effect of different stimulants, 104
- Cervical myelopathy, rheumatoid, and surgery, 200
- CHAMBERS RE, *see* Hutton CW.
- CHAN JKH, *see* Mackworth-Young CG.
- CHAPEL HM, *see* Byron MA.
- Characteristics of patients with serum antibodies to extractable nuclear antigens, 207
- CHARLES PJ, *see* Venables PJW.
- CHARTER RA, NEHEMKIS AM, KEENAN MA, PERSON D, PRETE PE. The nature of arthritis pain, 53
- CHASTY RC, *see* Brown KA.
- Cheiroarthropathy and frozen shoulder in diabetes, 76
- Chemotaxis, enhanced, of monocytes in RA, 83
- CHERIAN AM, *see* Srivastava A.
- CLAAS FHJ, *see* Breedveld FC.
- CLAGUE RB, *see* Klimiuk PS.
- CLELAND LG, *see* Hurst NP.
- DE CLERCK LS, WESTEDT ML, CATS A, VERMEER BJ, WELTEVEDEN EF, BRIDTS CH, STEVENS WJ. IgE-deposition in normal skin of patients with RA in relation to clinical and laboratory findings (A), 88
- Clinical measurement of the hand in scleroderma, its relationship to functional assessment, 96
- Clinical neuropathy in the assessment of neurological lupus, 207
- Clinical significance of tender points, 212
- Clinically significant vitamin C deficiency, 362
- COBB S, *see* Zoma A.
- COCHLIN D, *see* Rajan KT.
- COHEN B, *see* Forster PJG.
- COHEN SL, *see* Fisher C.
- COLACO CB, HARRIS G, LAWLEY PD, LYDYARD PM, ROITT IM. Defective DNA repair in RA families: evidence for a possible environmental factor (A), 107
- COLACO CB, MALE DK. Antiphospholipid antibodies in a thrombotic subset of SLE and in syphilis: distinguishing profiles of antibody activity (A), 75
- COLE BC, *see* Emery P.
- Collagen and proteoglycan, role in the mechanical behaviour of articular cartilage, 200
- Collagen immunity: seminar report, 298
- COLLIER L, *see* Armstrong RD.
- COLLINS CR, *see* Fisher C.
- Comparative study of the aetiological factors in shoulder pain, 24
- Comparative thickness, cell density and histochemistry of sacral and iliac cartilages in man, 90
- Comparison of
normal and pathological synovial fluid, 61
outbreak and sporadic cases of reactive arthritis, 112
reconstructive orthopaedic surgery in patients with seropositive and seronegative RA, 179
serum biochemistry in RA, seronegative arthropathies, SLE and normal controls, 205
the inflammatory response to a standard stimulus in patients with different rheumatic disease, 86
- Complement
component alleles in RA families, 106
fixation by anti-DNA in SLE: measurement by radioimmunoassay and relationship with disease activity, 83
- Compliance (E), 309
determinants of, in RA patients assessed in their home environment, 310
- Connective tissue disease, mixed, Sjögren's syndrome and abdominal pseudolymphoma, case report, 70
- Control of protein synthesis by dexamethasone in human PMNLs, 78
- Controlled study of
ketanserin in Raynaud's phenomenon, 97
oral prednisolone in frozen shoulder, 215

GENERAL INDEX

- Controlled two-centre trial, 101
- COOPER C, CAWLEY MID. Septic arthritis in an English Health District: a ten-year review (A), 197
- Copper
chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability, 128
iron, free radicals and arthritis (E), 123
screening tests based on *in vivo* interactions with, 137
- COPPOCK JS, ENGLAND S, HARRIS P, BACON PA. Clinical measurement of the hand in scleroderma, its relationship to functional assessment (A), 96
- COPPOCK JS, SCOTT DL, LUNEC J, ROBINSON M, BACON PA. Nephelometric determination of polyethylene glycol 'profiles' (A), 82
- COPPOCK JS, WOODS KL, HARDMAN J, KENDALL MJ, BACON PA. Local therapy for Raynaud's phenomenon re-examined (A), 96
- COPPOCK JS, *see also* Scott DGI; Struthers GR.
- Corticosteroid
injections, intra-articular, effect on proteoglycans in synovial fluid, 221
prescribing in RA—the fiction and the fact, 164, 380
treatment in RA (E), 125, 379, 380
- Corticosteroids, effects on bone mass in patients with asthma, PMR and RA, 215
- COUGHLAN R, *see* Mercer E.
- COUGHLAN RJ, CRISP AJ, PARR G, DEVEREAUX MD, THOMAS DP PAGE, HAZLEMAN BL. Algodystrophy: assessment by thermography and response to therapy with pulsed electromagnetic fields (A), 85
- COULTON BL, *see* Scott DL.
- CRAMB R, BEHN A. Serum selenium concentration and RA (A), 205
- CRAMP WA, HART LE, HARRIS G, EDWARDS JC, GEORGE AM, HUGHES GRV. Radiosensitivity of peripheral blood lymphocytes in auto-immune disease (A), 87
- CRANSTON WI, *see* Saklatvala J.
- CRAWLEY J, *see* Williams PL.
- C-reactive protein in synovial fluid and serum, 203
- CRISP AJ, MCGUIRE-GOLDRING MB, GOLDRING SR. A system for culture of human trabecular bone and hormone response profiles of derived cells (A), 99
- CRISP AJ, SMITH DA, WRIGHT JK, HAZLEMAN BL, DARBY AJ. A histological study of cultured human trabecular bone: effect of heparin and histamine (A), 98
- CRISP AJ, WRIGHT JK, HAZLEMAN BL. Heparin and histamine inhibit mouse calvarial bone turnover *in vitro* (A), 219
- CRISP AJ, *see also* Coughlan RJ.
- Crohn's disease, family survey of arthritis in, 208
- Cross-reacting anti-DNA idiotypes in skin biopsies from patients with SLE and discoid LE (A), 100
- CUPERUS RA, MUIJSERS AO, WEVER R, VAN DER KORST JK. Penicillamine and other thiol-containing drugs prevent the destructive action of myeloperoxidase released from activated leucocytes (A), 104
- CURREY HLF, *see* Kirk AP; Kirwan JR; Menashi S; Ollier W; Thompson PW.
- CURRIE JC, *see* Brandman S.
- Cytidine deaminase: a measure of synovial inflammation? 203
- Cytokines in RA, 94
- Cytomegalovirus (CMV), antibodies in SS and RA, 88
- Cytotoxicity of anti-Klebsiella serum for lymphocytes of AS patients from London, 216
- CZUDEK R, *see* Puttick AH.
- DALTROY H, *see* Robb-Nicholson C.
- DARBY AJ, *see* Crisp AJ.
- DAUNT SO'N, MILLIGAN JL. Effects of joint lavage on knee synovitis in RA (L), 378
- DAWES PT, SCOTT DL, FOWLER PD, JACKSON R, STONE R, SHADFORTH MF. Which rheumatoid patients show progressive joint damage while receiving slow-acting drugs? (A), 209
- DAWES PT, *see also* Oldroyd KG; Struthers GR.
- DAYER J-M. Cytokines in RA (A), 94
- Decreased chemiluminescent associated phagocytic response of peripheral blood MN to *Chlamydia trachomatis* in patients with HLA-B27+ anterior uveitis, 332
- Decreased expression of IL2 receptor on phytohaemagglutinin activated cells in RA, 109
- Defective DNA repair in RA families: evidence for a possible environmental factor, 107
- Defective immunity to EBV in AS, 87
- Defective regulation of EBV-induced lymphocyte activation in patients with RA, 90
- Deficient IL2 production by RA lymphocytes, 109
- Degradation of cartilage on contact with soft tissue, 98
- DELANGE G, *see* Sanders PA.
- Demonstration of gut abnormalities in RA using indium-111 leucocyte scanning, 204
- DENMAN AM. Immunomodulation and the rheumatic diseases (A), 222; *see also* Hylton W; Pelton BK.
- DENNY D, *see* Kirk AP.
- Dermal microvasculature in SS, 211
- DERUE G, *see* Harris EN.
- Desferrioxamine treatment for rheumatoid synovitis, 214
- Destructive spinal lesions of AS: stress fracture or mobile segment? 221
- Detection and partial characterization of human B-cell colony stimulating activity in synovial fluids of patients with RA, 206
- Determinants of compliance in RA patients assessed in their home environment, 313
- Development of screening tests for D-penicillamine-like antirheumatic activity based on *in vivo* interactions with copper, 137
- DEVEREAUX MD, *see* Coughlan RJ.
- Dexamethasone in control of protein synthesis, 78
- Diabetes mellitus, cheiroarthopathy and frozen shoulder in, 76
- Diagnostic value of synovial biopsy in patients with arthritis of unknown cause, 232
- DICKENS E, *see* Duff GW.
- DIEPPE P, ROGERS J. Two-dimensional epidemiology (E), 310
- DIEPPE PA, *see also* Carter SD; Doherty M; Fawthrop FW; Heywood A; Hutton CW; Macfarlane DG.
- Digital gangrene in autoimmune disease—is a new trial of therapy justified? 220
- 1,25-Dihydroxyvitamin D₃ enhancement of IL1 production from monocytes by, 108
inhibits lymphocyte proliferation and IL2 production: a potential new immunosuppressant, 110
- DINARELLO CA. New perspectives in IL1 biology (A), 95
- Direct immunofluorescence of normal skin in RA, 340
- Discoid LE, cross-reacting anti-DNA antibody idiotypes in skin biopsies, 100

GENERAL INDEX

- Distinct idiotypes of antigen binding sites of anti-La antibodies, 99
- Diuretic-induced gout in elderly women, 155
- DIXEY JJ, WILLIAMS TDM, LIGHTMAN SL, LANT AF, BREWERTON DA. The influence of indomethacin on the antidiuretic effect of vasopressin in normal man (A), 102
- DIXON JS, LOWE JR, BIRD HA. Serum and synovial fluid levels of angiotensin-converting enzyme in polyarthritis (A), 201
- DIXON JS, *see also* Bird HA; Sittou NG.
- DNA repair, defective, in RA families, 107
- DOBLE ATA, BUCKTON JB. Rabbit fibrinogen arthritis: chronicity without delayed hypersensitivity (A), 91
- DOEKES G, *see* Breedveld FC.
- Dog, naturally-occurring RA in, 198
- DOHERTY M, MACMILLAN P, WATT I, DIEPPE PA. A reappraisal of 'analgesic hip' (A), 91
- DOHERTY M, *See also* Fawthrop FW.
- Double-blind controlled trial of etretinate and ibuprofen in psoriatic arthritis, 102
- DOUGHERTY J, *see* Duff GW.
- DOYLE CT, *see* Finucane P.
- DOYLE DV, *see* Bourne JT.
- DUDENEY C, *see* Isenberg DA.
- DUFF GW. IL1 and fever (A), 93
- DUFF GW, DOUGHERTY J, DURUM SK, RON Y. Fever and the actions of interferon (A), 86
- DUFF GW, FORRE O, WAALLEN K, DICKENS E, NUKI G. RA synovial dendritic cells produce IL1 activity (A), 108
- DUKE O, HOBBS S, POULTER LW, PANAYI GS. An immunohistological analysis of the synovial membrane in AS (A), 80
- DUMONDE DC, *see* Brown KA.
- DUNN NA, LLOYD-JONES JK. The destructive spinal lesions of AS: stress fracture or mobile segment? (A), 221
- DUNN NA, *see also* Forsten PJG.
- Dupuytren's contracture and alcohol, 220
- DURUM S. IL1 in the immune response and the role of Ia molecules in IL1 production (A), 93; *see also* Duff GW.
- DYER P, *see* Grennan DM; Sanders PA.
- DYSON M, *see* Gibson T.
- EASTER J, *see* Robinson P.
- EASTMOND CJ, *see* Hendry PJ; Reid DM.
- EATON H, *see* Robb-Nicholson C.
- Echocardiography, 2-dimensional, in Libman-Sacks endocarditis, 187
- EDELMAN J, *see* Thompson RN.
- EDWARDS IR, *see* Campbell AJ.
- EDWARDS JC, *see* Cramp WA.
- EDWARDS JCW, SEDGWICK AD, MOORE AR, AL-DUAU A, WILLOUGHBY DA. Degradation of cartilage in contact with soft tissue (A), 98
- Effect of
- disease-modifying drugs on rheumatoid synovial membrane lymphocyte subsets, 216
 - gold therapy on RF synthesis by synovial membrane, 103
 - nonsteroidal anti-inflammatory therapy on plasma neuropeptide concentrations in patients with OA, 46
 - sulphasalazine on scavengers of oxygen-derived free radicals in RA, 91
- Effects of
- corticosteroids on bone mass in patients with asthma, PMR and RA, 215
 - joint lavage on knee synovitis in RA, 6, 378, 379
- Ehlers-Danlos syndrome, mutant locus in, 111
- ELLIS MI, WRIGHT V. Gait-analysis system (A), 199
- ELSON CJ, *see* Carter SD.
- EM changes in rectal mucosa of patients with RA, 204
- EMERY P, PANAYI GS, WELSH KI, COLE BC. The cellular immune defect of RA: the role of HLA status and the effect of different stimulants (A), 104
- Endocarditis, Libman-Sacks, 187
- ENGLAND S, *see* Coppock JS.
- ENGLERT H, *see* Harris EN.
- Enhanced chemotaxis of monocytes in RA, 83
- Enhanced oxidative metabolism of neutrophils in patients with PSS, 211
- Enhancement on IL1 production, 108
- Eosinophilia associated with naproxen, 302
- Epidemiology, two-dimensional, 310
- Epstein-Barr virus (EBV)
- antibodies to in SS and RA, 83
 - in AS, defective immunity to, 87
 - induced lymphocyte activation in RA, 90
- ESDAILE J, *see* Thompson RN.
- Etretinate and ibuprofen in psoriatic arthritis, 102
- Evaluating
- self-care activities: comparison of self-reported questionnaire with an occupational therapist interview, 357
 - the consequences of new consultant appointments in the North Western region, 210
- Evaluation of diagnostic criteria for AS: a comparison of the Rome, NY and modified NY criteria in patients with positive clinical history screening test for AS, 242
- EVANS DIK, *see* Holt PJL.
- EVANS HB, HOLT PJL, ASHERSON RA, MACKWORTH-YOUNG CG, HUGHES GRV. A new antibody in SLE (A), 101
- EVANS HB, *see also* Johnson PM.
- EVANS S, *see* Kirwan JR.
- Evolving concepts in rheumatology:
- abstracts of symposium, 222
 - seminar report, 300
- Excessive production of IL1 from MN of RA patients, 108
- Exclusion of the α_1 (II) collagen gene as the mutant locus in type I Ehlers-Danlos syndrome, 111
- FAGG N, *see* Gibson T.
- FAITH A, *see* Cambridge G.
- Family study of RA: the diagnostic value of RF tests (A), 105
- Family survey of arthritis in patients with ulcerative colitis and Crohn's disease, 208
- FARR M, SMITH P, BRODERICK A, BACON PA. Plasma and synovial fluid concentrations of sulphasalazine and the sulphapyridine derivative (A), 202
- FARR M, STRUTHERS GR, SCOTT DGI, BACON PA. Fenclofenac-induced selective IgA deficiency in RA, 367
- FAWTHROP FW, DOHERTY M, HUTTON C, HORNBY J, SWAN A, DIEPPE PA. Normal and pathological synovial fluid (A), 90
- FAWTHROP FW, HORNBY J, SWAN A, HUTTON C, DOHERTY M, DIEPPE P. A comparison of normal and pathological synovial fluid, 61
- FAY A, McMILLAN S, MCCREA J, TAGGART A, ROBERTS S, BOYD M, HAIRE M. Characteristics of patients with serum antibodies to extractable nuclear antigens, 207
- FAY A, TRUDGETT A, MCCREA J, KIRK F, THOMPSON J, MITCHELL E, BOYD M, ROBERTS S, MCNEILL T. Detection and partial characterization of human B-cell

GENERAL INDEX

- colony stimulating activity in synovial fluids of patients with RA (A), 206
- FEIGHERY C, *see* Hanly J.
- FELDMAN C, MASON P, JONES R, RUSSELL, KELLEY C. Femoral mycotic aneurism presenting as arthritis and purpura, 364
- FELDMAN M, *see also* Pirzad R.
- Felty's syndrome
in an Asian, 303
PMN cell directed auto-antibodies in, 84
- Femoral mycotic aneurysm presenting as arthritis and purpura, 364
- Fenclofenac-induced selective IgA deficiency in RA, 367
- FERRIE J, *see* Brown KA.
- FERRIS JB, *see* Finucane P.
- FERRY DG, *see* Campbell AJ.
- FESTENSTEIN H, *see* Ollier W.
- Fever
and the actions of interferon, 86
historical perspectives and evolution of modern views, 93
IL1 and, 93
- Fibrinogen arthritis, rabbit, 91
- Fibrinolytic activity in SS, 211
- Fibrodysplasia ossificans progressiva, 200
- Fibronectin production, 80
- FIELDING P, *see* Freemont AJ.
- Fingers, splinting of ruptured extensor tendons, 199
- FINUCANE P, DOYLE CT, FERRIS JB, MOLLOY M, MURNAGHAN D. Behçet's syndrome with myositis and glomerulonephritis, 372
- FISHER C, GIBB WRG, COHEN SL, COLLINS CR, POTTER A, ISENBERG DA. Lupus-like nephritis heralding the definitive manifestation of SLE, 256
- FISHER L, KURTZ A, SHIPLEY M. Association between cheiroarthropathy and frozen shoulder in patients with insulin-dependent diabetes mellitus (A), 76
- FITZGERALD O, HANLY J, CALLAN A, McDONALD K, MOLONY J, BRESHNIHAN B. Effects of joint lavage on knee synovitis in RA, 6, 379
- FITZGERALD OM, BARNES L, WOODS R, McHUGH L, BARRY C, O'LOUGHLIN S. Direct immunofluorescence of normal skin in RA, 340
- Flexor tenosynovitis in RA—effect of local steroid injections, 225
- FLUX W, *see* Owen SG.
- FORBES CD, *see* Belch JFF; Steven MM.
- FORDHAM JN, KING T, FURNEAUX C, PERRY JD. Rheumatoid cervical myelopathy and surgery (A), 200
- FORRE O, *see* Duff GW.
- FORSTER PJG, COHEN B, SPOWART G, STEEL CM, DUNN NA, NUKI G. Anticentromere antibodies in patients with chronic rheumatic diseases: preliminary clinical studies and characterization of antigens (A), 75
- FOWLER PD, *see* Dawes PT.
- FRAYHA R, *see* Mooradian AD.
- FRAYHA RA, NASR FW, MUFARRU AA. Mixed connective tissue disease, Sjögren's syndrome, and abdominal pseudolymphoma, 70
- FREEMONT AJ, FIELDING P, JAYSON MIV, JONES CJP. The dermal microvasculature in SS (A), 211
- FRENCH J, *see* Hurst NP.
- FRIESEN WT, *see* Owen SG.
- Frozen shoulder, cheiroarthropathy and, in diabetes, 76
- FURNEAUX C, *see* Fordham JN.
- Gait-analysis system, 198
- GALL V, *see* Robb-Nicholson C.
- Gangrene, digital, in autoimmune disease, 220
- GARDNER DL, BREKTON JD, HOLLINSHEAD MS. Comparative thickness, cell density and biochemistry of sacral and iliac cartilages in man (A), 90
- GARDNER DL, *see also* O'Connor P.
- GAVRILOVIC J, *see* Saklatvala J.
- GECZY AF, *see* Archer JR.
- GELSTHORPE K, *see* Lawrence JS.
- GEMMELL CG, *see* King SL.
- Gene locus in Ehlers-Danlos syndrome, 111
- GEORGE AM, *see* Cramp WA.
- Gerard cup, 199
- GHARAVI AE, SKOPOULI FN, PATEL BM, MADDISON PJ, MOUTSOPOULOS PJ, HUGHES GRV. Secretory IgA and IgM RFs in Ro-positive and Ro-negative RA (A), 87
- GHARAVI AE, *see also* Harris SN; Kennedy HG; Mackworth-Young CG.
- GIBB WRG, *see* Fisher C.
- GIBSON RA, *see* Smith MD.
- GIBSON T. Pain and pain relief: seminar report, 299; *see also* Armstrong RD; Griffin J.
- GIBSON T, BLAgrave P, HARKNESS J, WOO P, HILLS R, GRAHAME R. Low back pain treated by an osteopath—the first controlled study (A), 92
- GIBSON T, FAGG N, HIGHTON J, WILTON M, DYSON, M. The diagnostic value of synovial biopsy in patients with arthritis of unknown cause, 232
- GILBEY S, *see* Brailsford S.
- GIRGIS FL, *see* Withrington RH.
- Glomerulonephritis and myositis with Behçet's syndrome, 372
- β -Glucuronidase and IL1, adsorption by crystals, 200
- GLYN JH. Dr James Cyriax (Obit.), 376
- GLYNN D, *see* Mongey A-B.
- Gold-induced thrombocytopenia in patients with RA and the prediction of haemorrhagic diathesis by mean platelet volume, 204
- Gold therapy, effect of RF synthesis by synovial membrane, 103
- GOLDING DN, ROBERTSON MH. Reactive arthritis due to *Salm. schwarzengrund* in a patient with asymptomatic spondylitis, 194
- GOLDING SR, *see* Crisp AJ.
- Gonarthrosis, pain patterns in, 210
- GORDON D, *see* Lewis GP.
- GOSNELL N, *see* Ollier W.
- GOTTLIEB E, *see* Williams DG.
- Gout
and lead poisoning, spa therapy for, 208
diuretic-induced in elderly women, 155
- GRAHAM D, *see* Robinson P.
- GRAHAME R, *see* Gibson T; Griffin J; Kingsley G.
- Granulocytes in the rheumatoid synovial membrane demonstrated by monoclonal antibodies, 79
- GRENNAN DM, SANDERS PA, DYER P, HARRIS R. HLA haplotype sharing by RA sibs (A), 216
- GRENNAN DM, *see also* Sanders PA.
- GRIFFIN J, CELINSKA E, PANAYI GS, GIBSON T, GRAHAME R. A radiological study of seronegative and seropositive RA (A), 92
- GRIFFIN J, *see also* Kay A.
- GRIFFITHS ID, *see* Pal, B; Walker DJ.
- GRIFFITHS PD, *see* Venables PJW.
- GRINDULIS KA, SCOTT DL, ROBINSON MW, BACON PA,

GENERAL INDEX

- McConkey B. Serum amyloid A protein during the treatment of RA with second-line drugs, 158
- GUL V, *see* Haskard DO.
- GUSH R, *see* Longstaff J.
- Haemophilic arthritis, joint scans in, 263
- Haemorrhagic diathesis in gold-induced thrombocytopenia, 204
- HAIRE M, *see* Fay A.
- HAIJROUSOU V, *see* Snaith ML.
- HALL ND, *see* Maslen C.
- HAMBURGER J, *see* Scott DGI.
- Hand, clinical measurement of, in scleroderma, 96
- HANLY J, HASSAN J, MORIARTY M, WHELAN A, FEIGHERY C, CASEY E, MOLONY J, BRESNIHAN B. Lymphoid irradiation in RA: Comparison between 2000 rad and 750 rad (A), 102
- HANLY J, HASSAN J, WHELAN A, FEIGHERY C, BRESNIHAN B. The effect of gold therapy on RF synthesis by synovial membrane (A), 103
- HANLY J, *see also* FitzGerald O.
- HARDMAN J, *see* Coppock JS.
- HARKNESS J, *see* Gibson T.
- DE LA HARPE AL, *see* Brighton SW.
- HARRIS B, *see* Coppock JS.
- HARRIS EN, GHARAVI AE, DERUE G, ENGLERT H, LOIZOU S, PATEL B, ASHERSON R, HUGHES GRV. Antiphospholipid antibodies (A), 78
- HARRIS EN, *see also* Kennedy HG.
- HARRIS R, *see* Colaco CB; Cramp WA.
- HARRIS R, *see* Grennan DM.
- HART LE, *see* Cramp WA.
- HARTLEY H, *see* Robb-Nicholson C.
- HARVEY A, *see* Pelton BK.
- HARVIE R, *see* King SL.
- HASKARD DO, GUL V, ARCHER JR, HOLBOROW EJ. Monoclonal antibodies from patients with RA (A), 111
- HASKARD DO, *see also* Silman AJ.
- HASSAN J, *see* Hanly J.
- HAY FC, *see* Jones MG.
- HAZLEMAN BL, *see* Binder AI; Coughlan RJ; Crisp AJ; Mercer E; Smith AJ; Wright JK.
- HEARN JP, *see* Jones MG.
- HEATH JK, *see* Saklatvala J.
- HEINEGÅRD D, *see* Saxne T.
- HENDRY PJ, EASTMOND CJ. A comparison of outbreak and sporadic cases of reactive arthritis (A), 112
- HENRY JA. Compliance (E), 309
- Heparin
and histamine inhibit mouse calvarial bone turnover, *in vitro*, 219
effect of, on cultured human trabecular bone, 98
- Hepatitis B, 19
- HERBERT A, *see* Walters MT.
- HEROD E, *see* Klimiuk PS.
- HEWITT S, *see* Blake DR; Morris C.
- HEYWOOD A, O'HARE P, QUINNELL C, DIEPPE PA. 'Taking the cure'—spa therapy was an effective treatment for lead poisoning and gout (A), 208
- HIGGS L, *see* Hutton C.
- HIGHTON J, *see* Gibson T.
- HILL J, *see* Bird HA.
- HILLS R, *see* Gibson T.
- Hip, Gerard cup arthroplasty in, 199
- HIRSCHFIELD MS, *see* Spiegel JS.
- Histamine
and heparin inhibit mouse calvarial bone turnover *in vitro*, 219
effect of, on cultured human trabecular bone, 98
- Histological study of cultured human trabecular bone: effect of heparin and histamine, 98
- HLA
antigens in multiplex RA families—a preliminary report, 106
complement component alleles and immune complexes in RA families, 106
haplotype sharing by RA sibs, 216
B27+ anterior uveitis, 332
DR2, 104
DR3 and C4AQO alleles, raised in scleroderma, 212
- HOBBS RN, *see* Bernstein RM.
- HOBBS S, *see* Duke O.
- HOGG N, *see* Revell PA.
- HOLBOROW EJ, *see* Haskard DO.
- HOLDWORTH CD, *see* Lawrence JS.
- HOLLAND CD, *see* Keegan AL.
- HOLLINSHEAD MS, *see* Gardner DL.
- HOLLYWELL CA, *see* Struthers GR.
- HOLMES J, *see* Kirwan JR.
- HOLT PJL, EVANS DIK. Musculoskeletal problems in chronic bleeding disorders of childhood (A), 221
- HOLT PJL, *see also* Evans HB; Klimiuk PS; Schlecht BJM.
- HOPKINS DFC, BARNES RMR. Serum antibodies to bovine antigens in adult RA patients (A), 78
- HOPKINS R, *see* Bird HA.
- HORNBY J, *see* Fawthrop FW.
- HORROCKS A, *see* Armstrong RD.
- HORSEFALL AC, VENABLES PJW, MUMFORD PA, MELLOR CH, MAINI RN. Distinct idiotypes in antigen binding sites of anti-La antibodies (A), 99
- HOWE A, THOMPSON D, WRIGHT V. Microprocessor-mediated measurement of MCP joint stiffness (A), 220
- HUGHES GRV, *see* Bernstein RM; Cramp WA; Evans HB; Gharavi AE; Harris EN; Kennedy HG; Mackworth-Young CG.
- HUGHES JMB, *see* Kennedy HG.
- HUKINS DWL, *see* Aspdren RM.
- HULL RG, *see* Kennedy HG.
- HUNTER JA, *see* Capell H; Pullar T.
- HURST NP, BELL AL, NUKI G, O'DONNELL L, FRENCH J, CLELAND LG. Inhibition of phospholipid-transmethylation and methylation-dependent superoxide anion production in human monocytes by antimalarial drugs (A), 206
- HUTCHINSON M, *see* Mongey A-B.
- HUTTON C, HIGGS L, JACKSON PC, WATT I, DIEPPE PA. Technetium methylene diphosphonate isotope scans predict the progression of OA (A), 197
- HUTTON C, *see also* Fawthrop FW.
- HUTTON CW, WHICHER JT, CHAMBERS RE, DIEPPE PA. Comparison of the inflammatory response to a standard stimulus in patients with different rheumatic disease (A), 86
- HUTTON CW, *see* Carter SD.
- HYLTON W, CAYLEY J, DENMAN AM. Interferon-induced enzyme, 2,5-oligoadenylate synthetase, in autoimmune disease (A), 89
- Hypnosis and relaxation training, and biofeedback in chronic pain, 213
- Hypocholesterolaemia and abnormal high-density lipoprotein in RA, 250

GENERAL INDEX

- Ibuprofen and etretinate in psoriatic arthritis, 102
- Idiotypic interaction between RF and antipeptidoglycan antibodies? 198
- IgA and IgM RFs in RA, 87
- IgA deficiency in RA, fenclonac-induced, 367
- IgE-deposition in normal skin of patients with RA in relation to clinical and laboratory findings, 88
- IgG, synovial fluid, 203
- IgM RF, 203
- in vitro* synthesis, 81
- Ileocaecal inflammation due to NSAIDs: detection by indium-111 labelled leucocyte scans, 77
- Immune-complex solubilization, inhibition of, in RA, 110
- Immune complexes
- from sera, isolation and analysis, 82
- in RA families, 106
- Immune defect, cellular, of RA, 104
- Immune precipitation in SLE, prevention of, 82
- Immune response, IL1 in, 93
- Immunity, defective, to EBV in AS, 87
- Immunofluorescence, direct of normal skin in RA, 340
- Immunogenetic study of 22 patients with scleroderma: raised HLA DR3 and C4AQO alleles, 212
- Immunoglobulin heavy-chain allotypes (Gm) in RA—population and family studies, 105
- Immunohistological analysis of the synovial membrane in AS, 80
- Immunohistological and clinical studies of Sjögren's syndrome, 217
- Immunomodulation and the rheumatic diseases, 222
- Immunoreactive polypeptide components of La antigen, 100
- Immunosuppressant potential, new, 110
- In a lighter vein: the final report of the 1983 Anglo-US Fellows, 113; the 1984 Anglo-US travelling fellowships, 115
- Indium-111 labelled leucocyte scans for detection of ileocaecal inflammation due to NSAIDs, 77
- Indium-111 leucocyte scanning and gut abnormalities in RA, 204
- Indomethacin, influence on antidiuretic effect of vasopressin, 102
- Induction of angiogenesis by macrophages isolated from rheumatoid synovial tissue, 76
- Inflammation, synovial, iron storage and, 79
- Inflammatory joint disease, aetiology of, 222
- Inflammatory response to a standard stimulus in different rheumatic diseases, 86
- Influence of
- indomethacin on the antidiuretic effect of vasopressin in normal man, 102
- pregnancy on disease activity in RA: a prospective U.K./Netherlands study, 197
- Inhibition of
- immune-complex solubilization in RA, 110
- phagocytosis by RA sera, 205
- phospholipid transmethylation and methylation-dependent superoxide anion production in human monocytes by antimalarial drugs, 206
- Interaction of rheumatoid PMN with culture endothelium, 84
- Interferon
- actions of, fever and, 86
- induced enzyme, 2,5-oligoadenylate synthetase, in autoimmune disease, 89
- Interleukin 1 (IL1)
- activity produced by synovial dendritic cells, 108
- and fever, 93
- and β -glucuronidase, adsorption by crystals, 200
- biochemical perspective, 93
- biology, new perspectives in, 95
- excessive production from mononuclear cells of RA patients, 108
- in the immune response, and the role of Ia molecules in IL1 production, 93
- production
- by human monocytes, 107
- from monocytes enhanced by 1,25-dihydroxy-vitamin D₃, 108
- the pharmacologist's view, 94
- purification, and actions of a pig form of, 76
- Interleukin 2 (IL2)
- production
- and lymphocyte proliferation inhibited by 1,25-dihydroxy vitamin D₃, 110
- deficient, by RA lymphocytes, 109
- receptor on phytohaemagglutinin activated cells in RA, 109
- recombinant, reverses the depressed autologous mixed lymphocyte reaction in rheumatic diseases, 109
- Intervertebral disc function, classical model for, 219
- Intra-articular corticosteroid injections, effect on proteoglycans in synovial fluid, 221
- In vitro* study of the effect of a β -emitting isotope and mononuclear cell viability and lymphocyte proliferation, 85
- In vitro* synthesis of IgM RF by lymphocytes from RA patients and healthy subjects, 81
- Iron
- copper, free radicals and arthritis, 123
- deposits and tissue damage in the synovial membrane, 201
- storage and synovial inflammation, 79
- IRVING WL, WALKER P, LYDYARD PM. Defective regulation of EBV-induced lymphocyte activation in patients with RA (A), 90
- ISENBERG DA, DUDENEY C, BHOGAL BS, RAUCH J, WOJNARUSKA F. Cross-reacting anti-DNA antibody idiotypes in skin biopsies from patients with SLE and discoid LE (A), 100
- ISENBERG DA, *see also* Fisher C; Snaith ML.
- Isoxicam and piroxicam, pharmacokinetic projections for, 176
- JACKSON PC, *see* Hutton C.
- JACKSON R, *see* Dawes PT.
- JACOBY RK, *see* Puttick AH.
- JASANI MK, *see* Blowers LE.
- JAYSON MIV. Use of sequential analysis to assess patient preference for local skin anaesthesia during knee aspiration (L), 118
- JAYSON MIV, *see also* Blowers LE; Freemont AJ; Keegan AL; Longstaff J.
- JEANNET M, *see* Vischer TL.
- JENKINS JS, POWELL RJ, MAURICE P, LITTLEWOOD S, ALLEN BR. Thalidomide in the treatment of orogenital ulceration (A), 95
- JENKINS R, *see* Brandman S.
- JOHNSON PM, PHUA KK, EVANS HB. An idiotypic interaction between RF and antipeptidoglycan antibodies? (A), 199
- Joint
- damage,

GENERAL INDEX

- long-term, in RA, 209
 progressive, and slow-acting drugs, 209
 disease, inflammatory, aetiopathogenesis of, 212
 erosions, relationship of RF antigenic determinant, 86
 involvement, peripheral in PMR, 27
 lavage in knee synovitis, 1, 6, 378, 379
 mobility
 among University students in Iraq, 326
 devices for measuring, 82
 scans, radio-isotopic, in haemophilic arthritis, 263
 stiffness, MCP, measurement, 220
- JONES CJP, *see* Freemont AJ.
 JONES DD, *see* Thompson PW.
 JONES MG, HAY FC, CASHBURN-BUDD R, SHIPLEY ME, HEARN JP, ROITT M. Phylogenetic studies on the RF antigenic determinant: its relationship to joint erosions (A), 86
 JONES R RUSSELL, *see* Feldman C.
 JONES VE, *see* Puttick AH.
 JOSEPH AG, *see* Srivastava A.
 JOSLIN FG, *see* Arend WP.
- KAHAN A, AMOR B, DE VERNEJOUL F, SAPORTA L. Libman-Sacks endocarditis: the diagnostic importance of two-dimensional echocardiography, 187
 KAY A. Antirheumatic drugs in pregnancy and lactation (E), 230; *see also* Armstrong RD.
 KAY A, GRIFFIN J. The influence of pregnancy on disease activity in RA: a prospective U.K./Netherlands study (A), 197
 KEEGAN AL, HOLLAND CD, JAYSON MIV. Loss of diurnal variation in fibrinolytic activity in SS (A), 211
 KEENAN MA, *see* Charter RA.
 KELLY, C, *see* Feldman C.
 KENDALL MJ, *see* Coppock JS.
 KENNEDY HG, ASHERSON, RA, HULL RG, HARRIS EN, GHARAVI AE, HUGHES JMB, HUGHES GRV. Lung function and lupus anticoagulant (A), 95
 KENNEDY TD, WOODROW DF, MAINI RN. Morphometric quantitation of rheumatoid synovial membrane (A), 201
 KENNY D, *see* Kirk AP.
 KENTON P, *see* Barnes RMR.
 Ketanserin in Raynaud's phenomenon, 97
 KHAN MF, *see* Pullar T.
 KING SL, PARKER J, HARVIE, R, STURROCK RD, GEMMELL CG. Inhibition of phagocytosis by RA sera (A), 205
 KING T, *see* Fordham JN.
 KINGSLEY G, RIDLEY MG, GRAHAME R. Reiter's syndrome—a possible consequence of artificial insemination? 370
 KIRK AP, O'HARA B, McMULLIN J, MAGEED RAK, MENASHI S, ARCHER JR, CURREY HLF. An aggregate binding factor in cartilage (A), 97
 KIRK AP, PITT PI, KENNY D, BERRY H. Methyl prednisolone infusion in RA (L), 119
 KIRK AP, *see also* Brown KA.
 KIRK F, *see* Fay A.
 KIRWAN JR. Measuring the impact of RA (A), 222; *see also* Thompson PW.
 KIRWAN JR, EVANS S. Use of sequential analysis to assess patient preference for local skin anaesthesia during knee aspiration (L), 118
 KIRWAN JR, HOLMES J, CURREY HLF. measuring changes in RA—are rheumatologists able to perceive their own policies? (A), 81
- KLEIN F. Standardization and reliability of RF tests (L), 305
 KLIMIUK PS, HOLT PJL, CLAGUE RB, HEROD E. Gold-induced thrombocytopenia in patients with RA and the prediction of haemorrhagic diathesis by mean platelet volume (A), 204
 Klinefelter's syndrome and AS: does the X chromosome modify disease expression? 277
 KOCH AE, *see* Leibovich SJ.
 Knee
 aspiration, local skin anaesthesia during, 118
 joint, meniscus of, 218
 symptomatic OA of, 40
 synovitis in RA, joint lavage, 6, 378, 379
- KRANE, SM, *see* Bhalla AK.
 KURTZ A, *see* Fisher L.
- LAAJAM MA. Synovial rupture complicating Brucella arthritis, 191
 La antigen components identified using monoclonal antibodies, 100
 Lactation, antirheumatic medication during, 291
 LAFEVER GJM, *see* Breedveld FC.
 LANT AF, *see* Dixey JJ.
 LAURENT R, *see* Black CM.
 LAWLEY PD, *see* Colaco CB.
 LAWRENCE JS, HOLDWORTH CD, GELSTHORPE K, MORRELL G. A family survey of arthritis in patients with ulcerative colitis and Crohn's disease (A), 208
 LEA DJ, WARD DJ. The case against 'seronegative RA': a laboratory viewpoint (L), 225
 LEA DJ, *see also* Bernstein RM.
 LEDINGHAM JGG, *see* Byron MA.
 LEIBOVICH SJ, KOCH AE, POLVERINI PJ. Induction of angiogenesis by macrophages isolated from rheumatoid synovial tissue (S), 76
- Leucocyte
 metalloproteinases, 202
 scans, indium-111 labelled, 77
- LEWIS D, *see* Steven MM.
 LEWIS EJ, *see* Cashin CH.
 LEWIS GP, GORDON D. IL1—the pharmacologist's view (A), 94
 LEWIS PA. Methods of X-ray assessment in RA (L), 303
 LIANG M, *see* Robb-Nicholson C.
 Libman-Sacks endocarditis: the diagnostic importance of two-dimensional echocardiography, 187
 LIGHTMAN SL, *see* Dixey JJ.
 LINN S, *see* Lorber M.
 Lipoprotein, abnormal high-density, in RA, 250
 LITTLEWOOD S, *see* Jenkins JS.
 LLOYD-JONES JK, *see* Dunn NA.
 Local therapy for Raynaud's phenomenon re-examined, 96
 LOIZOU S, *see* Harris EN.
 LONGSTAFF J, GUSH, G, WILLIAMS EH, ROUTLEDGE R, JAYSON MIV. A controlled study of ketanserin in Raynaud's phenomenon (A), 97
 Long-term culture of human articular cartilage: stimulation of proteoglycan synthesis by serum and plasma, 218
 Long-term progression of joint damage in RA, 209
 LORBER M, AVIRAM M, LINN S, SCHARF Y, BROOK JG. Hypocholesterolaemia and abnormal high-density lipoprotein in RA, 250
 LORBER M, PANAYI GS. *In vitro* synthesis of IgM RF by lymphocytes from RA patients and healthy subjects (A), 81
 Loss of diurnal variation in fibrinolytic activity in SS, 211

GENERAL INDEX

- Low back pain treated by an osteopath—the first controlled study, 92
- LOWE GDO, *see* Steven MM.
- LOWE JR, *see* Dixon JS.
- LUNEC J, *see* Blake DR; Brailsford S; Coppock JS; Morris C.
- Lung function and lupus anticoagulant, 95
- Lupus-like nephritis heralding the definitive manifestation of SLE, 256
- Lupus, neurological, clinical neurophysiology in assessment of, 207
- LYDYARD PM, *see* Colaco CB; Irving WL.
- Lymph nodes—a potential site of lymphocyte activation in RA, 198
- Lymphocyte activation
in RA, 198
EBV-induced, 90
model 217
angiogenic factors: fact or fiction? 203
proliferation, effect of phosphorus-32 on, 85
proliferative responses to
bacterial antigens in B27-associated arthropathies, 106, 227
purified human skeletal muscle membranes, 74
reaction, autologous mixed, in rheumatic disease, reversed by IL2, 109
subsets, rheumatoid synovial membrane, 216
- Lymphocytes, AS, cytotoxicity of anti-Klebsiella serum for, 216
- Lymphocytotoxic autoantibodies in RA: relation to HLA-DR2, and titres of rheumatoid and antinuclear factors, 104
- Lymphoid irradiation in RA: comparison between 2000 rad and 750 rad, 103
- Lymphoma in Sjögren's syndrome: diagnostic significance of urinary monoclonal free light chains, 207
- MCARDLE B, *see* Belch JFF.
- MCCARTHY D, *see* Brown KA.
- MCCKEY B. Sulphasalazine in RA: Workshop report, 223; *see also* Grindulis KA; Situnayake RD.
- MCCREA J, *see* Fay A.
- MCDONALD K, *see* FitzGerald O.
- MACFARLANE DG, DIEPPE PA. Diuretic-induced gout in elderly women, 155
- MACFARLANE DG, *see also* Armstrong RD.
- MACFARLANE JD, *see* Berkhout B; Willems WJ.
- MCGUIRE-GOLDRING MB, *see* Crisp AJ.
- McHUGH L, *see* FitzGerald OM.
- MACKORTH-YOUNG CG, CHAN JKH, GHARAVI AE, BUNN CC, HUGHES GRV. Complement fixation by anti-DNA in SLE: measurement by radio-immunoassay and relationship with disease activity (A), 83
- MACKORTH-YOUNG CG, *see also* Evans HB.
- MCLAUGHLIN P, *see* Mercer E.
- MACMILLAN P, *see* Dieppe PA; Fay A.
- McMULLIN J, *see* Kirk AP; Menashi S.
- McNEILL T, *see* Fay A.
- MADDISON PJ, *see* Gharavi AE; Maslen C; Pereira RS.
- MADHOK R, *see* Belch JFF; Steven MM.
- MAGED RAK, *see* Kirk AP.
- MAINI RN, *see* Horsfall AC; Kennedy TD; Pirzad R; Venables PJW; Williams DG.
- MAKH SR, *see* Carter SD.
- MALE DK, *see* Colaco CB.
- MAPP PI, REVELL PA. Fibronectin production by synovial intimal cells (A), 80
- MASLEN C, WOLF AD, HALL ND, MADDISON PJ. Enhanced oxidative metabolism of neutrophils in patients with progressive SS (A), 211
- MASON P, *see* Feldman C.
- MASSONI RJ, *see* Arend WP.
- MATHEWS MB, *see* Bernstein RM.
- MATTHEWS JB, *see* Scott DGI.
- MAURICE P, *see* Jenkins JS.
- Measuring changes in RA—are rheumatologists able to perceive their own policies? (A), 81
- Measuring devices for studying joint mobility in the normal population, 82
- Measuring the impact of RA, 222
- MEHTA M. Recent advances in pain treatment, 213
- MELLOR CH, *see* Horsfall AC.
- MELSON RD, *see* Venables PJW.
- MENASHI S, McMULLIN J, URBAN J, REVELL PA, CURREY HLF. Long-term culture of human articular cartilage: stimulation of proteoglycan synthesis by serum and plasma (A), 218; Topographical variation of proteoglycan synthesis by cartilage of human femoral condyle (A), 219
- MENASHI S, *see also* Kirk AP.
- MERCER E, CAWSTON TE, DE SILVA M, HAZLEMAN BL. Purification of a metalloproteinase inhibitor from human rheumatoid synovial fluid (A), 202
- MERCER E, COUGHLAN R, MCLAUGHLIN P, CAWSTON T, HAZLEMAN B. Synovial fluids from infected joints contain active leucocyte metalloproteinases and no inhibitory activity (A), 202
- Metalloproteinase inhibitor, purification of, 202
- Metalloproteinases
active leucocyte, 202
tissue inhibitors of, 85
- Methods of X-ray assessment in RA: a re-evaluation, 31, 303
- Methotrexate therapy, parenteral, for refractory RA, 101
- Methyl prednisolone infusion in RA, 119
- β_2 -Microglobulin binding activity in sera from patients with SLE: relationships between serum binding to DNA and other ligands, 77
- Microprocessor-mediated measurement of MCP joint stiffness, 220
- MILLER A, *see* Bird HA.
- MILLIGAN JL, *see* Daunt SO'N.
- MITCHELL E, *see* Fay A.
- MITCHELL WS, WHALEY K. Inhibition of immune-complex solubilization in RA (A), 110
- Mixed connective tissue disease, Sjögren's syndrome, and abdominal pseudolymphoma, 70
- MOLLOY M, *see* Finucane P.
- MOLONY J, *see* FitzGerald O; Hanly J.
- MONGEY A-B, GLYNN D, HUTCHINSON M, BRESNIHAN B. Clinical neurophysiology in the assessment of neurological lupus (A), 207
- Monoclonal antibodies
demonstrating granulocytes, 79
from patients with RA, 111
- Monocyte-endothelial cell interaction, inhibited by benoxaprofen, 84
- Monocytes, enhanced chemotaxis of, in RA, 83
- Mononuclear cell viability, effect of phosphorus-32, 85
- MOORADIAN AD, FRAYHA R. Multiple vasculopathies and hepatitis B in a family, 19
- MOORE AR, *see* Edwards JCW.

GENERAL INDEX

- MOORE K, *see* Walters MT.
MORIARTY M, *see* Hanly J.
Morphometric quantitation of rheumatoid synovial membrane, 201
MORRELL G, *see* Lawrence JS.
MORRIS C, BLAKE DR, HEWITT S, YOSHINO S, LUNEC J, BACON PA. Iron storage and synovial inflammation (A), 79
MORRIS CJ, BLAKE DR, WAINWRIGHT AC. Iron deposits and tissue damage in the synovial membrane (A), 201
MORRIS CJ, *see also* Blake DR; Struthers GR.
Mouse calvarial bone turnover *in vitro*, 219
MOUTSOPOULOS HM, *see* Gharavi AE.
MOWAT AG, *see* Bradlow A; Byron MA.
MUFARRIJ AA, *see* Frayha RA, 70
MUIJSERS AO, *see* Cuperus RA.
Multiple vasculopathies and hepatitis B in a family, 19
MUMFORD PA, *see* Horsfall AC.
MURNAGHAN D, *see* Finucane P.
MURPHY P. IL1: biochemical properties (A), 93
Muscle membranes, human skeletal, 74
Musculoskeletal problems in chronic bleeding disorders of childhood, 221
Myeloperoxidase released from activated leucocytes, 104
MYLES AB. Corticosteroid treatment in RA (E), 125; (L), 379
Myositis
 and glomerulonephritis with Behçet's syndrome, 372
 (fibrodysplasia) ossificans progressiva: diagnosis, natural history and treatment in 22 cases, 200
 sera with separate antibodies to alanyl-tRNA synthetase and transfer RNA, 101
Naproxen, pulmonary infiltrates and eosinophilia associated with, 302
NASR FW, *see* Fraya RA.
Nature of arthritis pain, 53
NEEDS C, *see* Brooks P.
NEEDS CJ, BROOKS PM. Antirheumatic medication during lactation, 291; Antirheumatic medication in pregnancy, 282
NEHEMKIS AM, *see* Charter RA.
Nephelometric determination of polyethylene glycol 'profiles', 82
Neuropeptide concentration in plasma of OA patients, effect of NSAIDs, 46
Neutrophils, enhanced oxidative metabolism of, in PSS, 211
New antibody in SLE, 101
New perspectives in IL1 biology, 95
NEWTON P, *see* Thompson RN.
NICOLL JJ, *see* Reid DM.
NIVED O, STURFELT G, WOLLHEIM F. SLE in an adult population in Southern Sweden: incidence, prevalence and validity of ARA revised classification criteria, 147
NOBLE DP, *see* Wright JK.
Nodules, rheumatoid, developing over amputation stumps, 378
Nonsteroidal anti-inflammatory therapy, effect of, on plasma neuropeptide concentrations in patients with OA, 46
Normal and pathological synovial fluid, 90
NOURI AME, PANAYI GS, WAUGH APW. Deficient IL2 production by RA lymphocytes (A), 109; Excessive production of IL1 from mononuclear cells of RA patients (A), 108
NSAIDs, ileocaecal inflammation due to, 77
NUKI G, *see* Duff GW; Forster PJG; Hurst NP; Reid DM.
OA progression predicted by MDP isotope scans, 197
Obituary: Dr James Cyriax, 376
O'CONNOR P, ORFORD CR, GARDNER DL. Role of proteoglycan and collagen in the mechanical behaviour of articular cartilage (A), 200
O'DONNELL L, *see* Hurst NP.
O'DOWD A, *see* Belch JIF.
OGILVIE L, *see* Wordsworth P.
O'HARA B, *see* Kirk AP.
O'HARE P, *see* Heywood A.
OLDROYD KG, DAWES PT. Clinically significant vitamin C deficiency in RA, 362
2,5-Oligoadenylate synthetase, interferon-induced enzyme in auto-immune disease, 89
OLLIER W, SILMAN A, GOSNELL H, CURREY H, FESTENSTEIN H. HLA antigens in multiplex RA families—a preliminary report (A), 106
O'LOUGHLIN S, *see* FitzGerald OM.
ORFORD CR, *see* O'Connor P.
Orogenital ulceration, thalidomide treatment of, 95
Orthopaedic surgery, reconstructive in RA, 179
Osteoarthritis,
 early stages of, and stiffness of articular cartilage across total joint surfaces, 219
 in a rural African community, 321
 symptomatic, of the knee, 40
Osteomalacia, Paget's disease and, 97
Osteopath, low back pain treated by, 92
Osteopathy, scientific research in, 2
O'SULLIVAN M, AMOS N, WILLIAMS BD. RF inhibits the ability of serum to maintain antigen-antibody complexes in solution (A), 83
O'SULLIVAN M, WALKER D MURRAY, WILLIAMS BD. Reticulo-endothelial Fc receptor function in patients with Sjögren's syndrome (A), 89
OWEN SG, FRIESEN WT, ROBERTS MS, FLUX W. Determinants of compliance in RA patients assessed in their home environment, 313
Paget's disease and osteomalacia, 97
PAICE EW, *see* Binder AI.
Pain,
 and pain relief, seminar, abstracts, 212; report, 299
 arthritis, nature of, 53
 chronic, biofeedback, hypnosis and relaxation training in, 213
 mechanisms: recent advances in the study of the neurobiology of pain, 213
 patterns in gonarthrosis, 210
PAL B, GRIFFITHS ID. Rheumatoid nodules developing over amputation stumps (L), 378
PALMER DG, *see* Revell PA.
PALMOSKI MJ, *see* Brandt K.
PANAYI GS. The aetiopathogenesis of inflammatory joint disease (A), 222; *see also* Armstrong RD; Duke O; Emery P; Griffin J; Lorber M; Mills M McKenzie; Nouri AME; Robinson S.
PARKER J, *see* King SL.
PARKER JD, CALDER V, CAPELL HA. An 'acute arthritis clinic'—one year's experience, 210
PARR G, *see* Binder AI; Coughlan RJ.
Parvovirus infection, human, arthritis induced by, 74
PATEL B, *see* Harris EN.

GENERAL INDEX

- PATEL BM, *see* Gharavi AE.
- Patterns of antihistone antibody specificity in systemic rheumatic disease, 99
- PELL PA, *see* Sheldon PJ.
- PELTON BK, HARVEY A, DENMAN AM. Rheumatoid synovial membranes participate in systemic antibody responses (A), 74
- Penicillamine and other thiol-containing drugs prevent the destructive action of myeloperoxidase released from activated leucocytes, 104
- D-Penicillamine-like antirheumatic activity, 137
- PENNY R, *see* Wakefield D.
- PEREIRA RS, BLACK CM, BRIGGS D, WELSH KI, and the UK Scleroderma Study Group. An immunogenetic study of 22 patients with scleroderma: raised HLA DR3 and C4AQO alleles (A), 212
- PEREIRA RS, MADDISON PJ, and the UK Scleroderma Study Group. Antinuclear antibodies in the families of patients with SS (A), 212
- Peripheral blood lymphocytes in autoimmune disease, radiosensitivity of, 87
- Peripheral joint involvement in PMR: a clinical study of 56 cases, 27
- PERRY JD, *see* Brown KA; Fordham JN.
- PERSON D, *see* Charter RA.
- Phagocytic response of peripheral blood MN in patients with HLA-B27+ anterior uveitis, 332
- Phagocytosis, inhibition by RA sera, 205
- Pharmacokinetic comparison of tenoxicam in plasma and synovial fluid, 351
- Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects, 176
- Phospholipid-transmethylation, inhibition by antimalarial drugs, 206
- Phosphorus-32 effect on mononuclear cell viability and lymphocyte proliferation, 85
- PHUA KK, *see* Johnson PM.
- Phylogenetic studies on the RF antigenic determinant: its relationship to joint erosions, 86
- PILSWORTH LMC, *see* Saklatvala J.
- Piroxicam and isoxicam, pharmacokinetic projections for, 176
- PIRZAD R, PLATER-ZYBERK C, FELDMANN M, MAINI RN. Decreased expression of IL2 receptor on phytohaemagglutinin activated cells in RA (A), 109
- PITT PI, *see* Kirk AP.
- Plasma and synovial fluid concentrations of sulphasalazine and the sulphapyridine derivative, 202
- Platelet sensitivity to a prostacyclin (PGI₂) analogue in SS, 91, 346
- PLATER-ZYBERK C, *see* Pirzad R.
- POLVERINI, PJ, *see* Leibovich SJ.
- Polyarthritis, angiotensin-converting enzyme in, 201
- Polyethylene glycol 'profiles', nephelometric determination, 82
- Polymorphonuclear cell directed auto-antibodies in patients with Felty's syndrome, 84
- Polymorphonuclear cell, rheumatoid, interaction with cultured endothelium, 84
- Polymorphonuclear leucocytes, protein synthesis in, 78
- Polymyalgia rheumatica
effects of corticosteroids on bone mass in patients, 215
peripheral joint involvement in, 27
- PONSFORD FM, *see* Carter SD.
- POPERT AJ. Rice-bodies, synovial debris, and joint lavage (E), 1; *see also* Scott DL.
- POTTER A, *see* Fisher C.
- POTTS J, *see* Scott DGI.
- POULTER LW, *see* Duke O.
- POUND JD, *see* Walker DJ.
- POWELL RJ, *see* Jenkins JS; Walker DJ.
- Practical results of treatment with disease-modifying antirheumatoid drugs, 167
- Prednisolone, oral, for frozen shoulder, 215
- Pregnancy
and lactation, antirheumatic drugs in, 230
antirheumatic medication in, 282, 382
influence on disease activity in RA, 197
- PRETE PA, *see* Charter RA.
- Prevalence of OA in a rural African community, 321
- Prevention of immune precipitation in SLE, 82
- Primary sicca syndrome, CMV and EBV antibodies to, 88
- Production of tissue inhibitors of metalloproteinases to human synovial cells *in vitro*, 85
- Prostacyclin analogue, platelet sensitivity to in SS, 91, 346
- Protein synthesis by dexamethasone in PMNLs, 78
- Proteins, acute-phase, 94
- Proteoglycan
and collagen role in the mechanical behaviour of articular cartilage, 200
synthesis
by serum and plasma, 218
in cartilage of human femoral condyle, 219
- Proteoglycans in synovial fluids: effect of intra-articular corticosteroid injections, 221
- Pseudolymphoma, abdominal, 70
- Psoriatic arthritis, etretinate and ibuprofen in, 102
- Psychophysiological determinants of fatigue in SLE, 110
- PULLAR T. Screening for new antirheumatic drugs (L), 381
- PULLAR T, HUNTER JA, CAPELL HA. Relationship of dose and serum levels to efficacy of sulphasalazine in RA (A), 103; Sulphasalazine in the treatment of RA: relationship of dose and serum levels to efficacy, 269; Toxicity of sulphasalazine in patients with RA (A), 214
- PULLAR T, HUNTER JA, CAPELL HA, ZOMA A. Effect of sulphasalazine on scavengers of oxygen-derived free radicals in RA (A), 91
- Pulmonary infiltrates and eosinophilia associated with naproxen, 302
- Pulsed electromagnetic fields for algodystrophy, 85
- Purification
and actions of a pig form of IL1, 76
of a metalloproteinase inhibitor from human rheumatoid synovial fluid, 202
- Purpura and arthritis, femoral mycotic aneurysm presenting as, 364
- PUTTICK AH, BRIGGS D, CZUDEK R, WILLIAMSON EA, JACOBY RK, JONES VE. HLA, complement component alleles and immune complexes in RA families (A), 108
- QUINNELL C, *see* Heywood A.
- Rabbit fibrinogen arthritis: chronicity without delayed hypersensitivity, 91
- Radio-immunoassay measurement of complement fixation, 83
- Radio-isotopic joint scans in haemophilic arthritis, 263
- Radiological study of seronegative and seropositive RA, 92
- Radiosensitivity of peripheral blood lymphocytes in autoimmune disease, 87
- RAJAN KT, BARR WT, WILLIAMS ED, COCHLIN D, BROUGHTON RBK. Paget's disease and osteomalacia (A), 97

GENERAL INDEX

- Rapid and reproducible method for the isolation and analysis of immune complexes from sera, 82
- Rapid reversibility of changes in articular cartilage induced by compressive stress, 98
- RAUCH J, see Isenberg DA.
- Raynaud's phenomenon, ketanserin in, 97
- local therapy for, 96
- Reactive arthritis due to *Salm. schwarzengrund* in a patient with asymptomatic spondylitis, 194
- Reappraisal of 'analgesic hip', 91
- Recent advances in pain treatment, 213
- Recombinant IL2 reverses the depressed autologous mixed lymphocyte reaction in rheumatic diseases, 109
- Re-evaluation of PMN directed auto-antibodies in patients with Felty's syndrome, 84
- REID DM, NICOLL JJ, BROWN N, SMITH MA, TOTHILL P, NUKI G. Effects of corticosteroids on bone mass in patients with asthma, PMR and RA (A), 215
- REID DM, REID TMS, BROWN T, RENNIE JAN, EASTMOND CJ. Arthritis induced by human Parvovirus infection (A), 74
- REID TMS, see Reid DM.
- Reiter's syndrome—a possible consequence of artificial insemination, 370
- Relationship of dose and serum levels to efficacy of sulphasalazine in RA, 103
- RENNIE JAN, see Reid DM.
- Report, final, of the 1983 Anglo-US Fellows, 113
- The 1984 Anglo-US Travelling Fellowships, 115
- Resin-coated 5-aminosalicylic acid (Asacol) in RA, 226
- Reticulo-endothelial Fc receptor function in patients with Sjögren's syndrome, 89
- REVELL PA, HOGG N, PALMER DG. Granulocytes in the rheumatoid synovial membrane demonstrated by monoclonal antibodies (A), 79
- REVELL PA, see also Mapp PJ; Menashi S.
- Reviews of books, 120, 228, 306, 383
- Rheumatic disease, systemic, patterns of antihistone antibody specificity in, 99
- Rheumatic diseases, chronic, anticitromere antibodies in patients with, 75
- different, inflammatory response in, 86
- immunomodulation and, 222
- Rheumatoid arthritis antibodies to bovine antigens in adult patients, 78
- CMV and EBV in, 88
- assessment of self-care activities, 357
- cellular immune defect of, 104
- corticosteroid treatment in, 125, 379, 380
- effects on bone mass, 215
- cytokines in, 94
- defective regulation of EBV induced lymphocyte activation, 90
- diagnostic value of RF tests, 105
- effect of sulphasalazine on scavengers of oxygen-derived free radicals, 91
- effects of joint lavage on knee synovitis in RA, 6, 378, 379
- enhanced chemotaxis of monocytes in, 83
- excessive production of IL1 from mononuclear cells of RA patients, 108
- families defective DNA repair in, 107
- HLA, complement component alleles and immune complexes in, 106
- fenclofenac-induced IgA deficiency, 367
- flexor tenosynovitis in, 225
- gold-induced thrombocytopenia in, 204
- HLA haplotype sharing by sibs, 216
- hypocholesterolaemia and high-density lipoprotein in, 250
- IgE deposition in skin, 88
- IgM RF factor synthesis, 81
- immunofluorescence, direct, of normal skin, 340
- immunoglobulin heavy-chain allotypes, 105
- indium-111 leucocyte scanning for gut abnormalities, 204
- joint damage, long-term, 209
- knee synovitis, effects of joint lavage, 6, 378, 379
- lymph nodes—a potential site of lymphocyte activation, 198
- lymphocytes, deficient IL2 production by, 109
- lymphocytotoxic auto-antibodies in, 104
- lymphoid irradiation in, 103
- measuring changes in, 81
- the impact of, 222
- methods of X-ray assessment in, 31, 303, 304
- methyl prednisolone infusion in, 119
- monoclonal antibodies from patients with, 111
- naturally-occurring in the dog, 198
- pregnancy, influence on disease activity of, 197
- rectal mucosa, EM changes in, 204
- refractory, methotrexate therapy for, 101
- resin-coated 5-aminosalicylic acid (Asacol) in, 226
- secretory IgA and IgM RFs in, 87
- sera, inhibition of phagocytosis by, 205
- seronegative and seropositive, comparison of reconstructive orthopaedic surgery in, 179
- 'seronegative', the case against, 225
- seropositive and seronegative, radiological study, 92
- serum amyloid A protein during treatment with second-line drugs, 158
- serum biochemistry in seronegative arthropathies, SLE and, 205
- serum selenium concentration, 205
- splinting of ruptured extensor tendons of fingers, 199
- stanazolol as a treatment for, 102
- sulphasalazine in, 103, 269
- active moiety in, 215
- toxicity, 214
- Workshop report, 223
- synovial dendritic cells produce IL1 activity, 108
- synovial fluids, human B-cell colony stimulating activity in, 206
- synovial macrophage dysfunction in, 80
- transferrin receptor bearing cells in, 217
- vitamin C deficiency in, 362
- Rheumatoid cervical myelopathy and surgery, 200
- Rheumatoid factor (RF) antigenic determinant, phylogenetic studies, 86
- IgM *in vitro* synthesis, 81
- inhibits the ability of serum to maintain antigen-antibody complexes in solution, 83
- interaction with antipeptidoglycan antibodies, 198
- tests, standardization and reliability, 305
- Rheumatoid factors, secretory IgA and IgM in RA, 87
- Rheumatoid nodules developing over amputation stumps, 378

GENERAL INDEX

- Rheumatoid PMN—interaction with cultured endothelium, 84
- Rheumatoid synovial membrane, morphometric quantitation of, 201
- Rheumatoid synovial membranes participate in systemic antibody responses, 74
- Rheumatoid synovial tissue, induction of angiogenesis by macrophages from, 76
- Rheumatology, evolving concepts in, abstracts of symposium, 222; seminar report, 300
- Rice-bodies, synovial debris, and joint lavage, 1
- RIDLEY MG, *see* Kingsley G.
- RNA and immunoreactive polypeptide components of La antigen (SSB) identified using monoclonal antibodies, 100
- ROBB-NICHOLSON C, LIANG M, DALTRY L, EATON H, GALL V, SCHWARZ J, HARTLEY H, SCHUR P. Psychophysiological determinants of fatigue in SLE (A), 110
- ROBERTS MS, *see* Owen SG.
- ROBERTS NA, CASHIN CH. Screening for new antirheumatic drugs (L), 381
- ROBERTS NA, ROBINSON PA. Copper chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability, 128
- ROBERTS S, *see* Fay A.
- ROBERTSON MH, *see* Golding DN.
- ROBINSON M, *see* Coppock JS.
- ROBINSON MW, *see* Grindulis KA.
- ROBINSON P, *see* Wakefield D.
- ROBINSON PA, *see* Roberts NA.
- ROBINSON S, PANAYI GS. Defective immunity to EBV in AS (A), 87
- ROITT IM, *see* Colaco CB.
- Role of proteoglycan and collagen in the mechanical behaviour of articular cartilage, 200
- RON Y, *see* Duff GW.
- ROUTLEDGE R, *see* Longstaff J.
- ROZING PM, *see* Willems WJ.
- RUSSELL AS, *see* Thompson RM.
- RUSSELL JG. Antirheumatic medication in pregnancy (L), 382
- SAKLATVALA J, SARSFIELD SJ, PILSWORTH LMC, HEATH JK, GAVRILOVIC J, CRANSTON WI, STARUCH MJ. Purification and actions of a pig form of IL1 (A), 76
- SALMON M, BACON PA, SYMMONS DPM. Transferrin receptor bearing cells in RA and an *in vitro* model of lymphocyte activation (A), 217
- SANDERS PA, DELANGE G, DYER P, GRENNAN DM. Immunoglobulin heavy-chain allotypes (Gm) in RA—population and family studies (A), 105
- SANDERS PA, *see also* Grennan DM.
- SAPORTA L, *see* Kahan A.
- SARSFIELD SJ, *see* Saklatvala J.
- SAXNE T, HEINEGÅRD D, WOLLHEIM FA. Proteoglycans in synovial fluid: effect of intra-articular corticosteroid injections, 221
- SCHARF Y, *see* Lorbet M.
- SCHLECHT BJM, HOLT BJL, WOOD PHN. Pain patterns in gonarthrosis (A), 210
- SCHUR P, *see* Robb-Nicholson C.
- SCHWARZ J, *see* Robb-Nicholson C.
- Scientific research in osteopathy, 2
- Scleroderma, clinical measurement of the hand in, 96
- immunogenetic study, 212
- SCOTT DGI, HAMBURGER J, STRUTHERS GR, COPPOCK J, POTTS J, MATTHEWS JB. Sjögren's syndrome: clinical and immunohistological studies (A), 217
- SCOTT DGI, *see also* Farr M; Struthers GR.
- SCOTT DL. Methods of X-ray assessment in RA (L), 304; *see also* Coppock JS; Dawes PT; Grindulis KA.
- SCOTT DL, COULTON BL, BACON PA, POPERT AJ. Methods of X-ray assessment in RA: a re-evaluation, 31
- SCOTT DL, COULTON BL, POPERT AJ. The long-term progression of joint damage in RA (A), 209
- Screening for new antirheumatic drugs, 381
- Scrutiny of the classical model for intervertebral disc function, 219
- Secretory IgA and IgM RFs in Ro-positive and Ro-negative RA, 87
- SEDGWICK AD, *see* Edwards JCW.
- SEEDHOM BB, *see* Swann AC.
- SEGAL AW, *see* Snaith ML.
- SEIFERT MH, *see* Withington RH.
- Selenium concentration, serum and RA, 205
- Self-care activities, evaluating, 357
- Septic arthritis in an English Health District: a ten-year review, 197
- Seronegative arthropathies, serum biochemistry in, 205
- 'Seronegative RA', the case against, 225
- Serum amyloid A protein during the treatment of RA with second-line drugs, 158
- and synovial fluid levels of angiotensin-converting enzyme in polyarthritis, 201
- antibodies to bovine antigens in adult RA patients, 78
- selenium concentration and RA, 205
- SHADFORTH MF, *see* Dawes PT
- SHEEHAN NJ. Pulmonary infiltrates and eosinophilia associated with naproxen (L), 302; *see also* Brown KA.
- SHELDON PJ, PELL PA. Lymphocyte proliferative responses to bacterial antigens in B27-associated arthropathies, 11; (A), 106
- SHELDON PJ, WEBB C. *In vitro* study of the effect of a β -emitting isotope on mononuclear cell viability and lymphocyte proliferation (A), 85
- SHINE B, *see* Bourne JT.
- SHIPLEY M, *see* Fisher L; Jones MG.
- Shoulder, frozen, oral prednisolone for, 215
- pain, 24
- SILMAN AJ, HASKARD DO. Measuring devices for studying joint mobility in the normal population (A), 82
- SILMAN AJ, *see also* Ollier W.
- DE SILVA M, *see* Mercer E.
- SIMMONS K, *see* Brown KA.
- SITON NG, DIXON JS, WRIGHT V. RA, seronegative arthropathies, SLE and normal controls (A), 205
- SITUNAYAKE RD, MCCONKEY B. Resin-coated 5-aminosalicylic acid (Assacol) in RA (L), 226
- Sjögren's syndrome clinical and immunohistological studies, 217
- lymphoma in, 207
- mixed connective tissue disease, and abdominal pseudolymphoma, 70
- reticulo-endothelial Fc receptor function in, 89
- SKOPOULI FN, *see* Gharavi AE.
- SLE *see* Systemic lupus erythematosus
- SMEATHERS JE. Scrutiny of the classical model for intervertebral disc function (A), 219
- SMITH AJ, CAWSTON TE, HAZLEMAN BL. A rapid and reproducible method for the isolation and analysis of immune complexes from sera (A), 82

GENERAL INDEX

- SMITH DA, *see* Crisp AJ.
 SMITH JL, *see* Walters MT.
 SMITH MA, *see* Reid DM.
 SMITH MD, GIBSON RA, BROOKS PM. Abnormal bowel permeability in arthritis—relationship to disease activity and spondylitis (A), 77
 SMITH P, *see* Farr M; Thompson RN.
 SMITH PR, *see* Williams DG.
 SMITH R, *see* Bradlow A; Wordsworth P.
 SMITH WE, *see* Pullar T.
 SMYTHE H. The clinical significance of tender joints (A), 212
 SNAITH ML, ISENBERG DA, HAJIROUSOU V, TOLFREE S, SEGAL AW. Demonstration of gut abnormalities in RA using indium-111 leucocyte scanning (A), 204
 SNAITH ML, *see also* Cambridge G.
 Some characteristics of naturally-occurring RA in the dog, 198
 Spa therapy for lead poisoning and gout, 208
 SPIEGEL JS, HIRSHFIELD MS, SPIEGEL TM. Evaluating self-care activities: comparison of a self-reported questionnaire with an occupational therapist interview, 357
 SPIEGEL TM, *see* Spiegel JS.
 Spinal lesions, destructive, of AS, 221
 Splinting of ruptured extensor tendons of the fingers in patients with RA, 199
 Spondylitis, asymptomatic, 194
 SPOWART G, *see* Forster PJG.
 SRIVASTAVA A, JOSEPH AG, CHERIAN AM. Felty's syndrome in an Asian (L), 303
 Standardization and reliability of RF tests, 305
 STANLEY JK, *see* Thompson RN.
 Stanozolol as a treatment for RA (A), 102
 STARUCH MJ, *see* Seklatvala J.
 Statistical adviser to *BJR*: Methods of X-ray assessment in RA (L), 304
 STEEL CM, *see* Forster PJG.
 STEITZ JA, *see* Williams DG.
 Steroid injections, local in flexor tenosynovitis in RA, 225
 STEVEN MM, LEWIS D, MADHOK R, LOWE GDO, STURROCK RD, FORBES CD. Radio-isotopic joint scans in haemophilic arthritis, 263
 STEVEN MM, *see also* The HSG.
 STEVENS WJ, *see* De Clerck LS.
 STEVENSON FK, *see* Walters MT.
 STONE R, *see* Dawes PT.
 Structure and failure of the meniscus of the knee joint, 218
 STRUTHERS GR, COPPOCK JS, SCOTT DGI, DAWES PT, BACON PA. Digital gangrene in autoimmune disease—is a new trial of therapy justified? (A), 220
 STRUTHERS GR, HOLLYWELL CA, MORRIS CJ, WALTON KW, BACON PA. EM changes in the rectal mucosa of patients with RA (A), 204
 STRUTHERS GR, *see also* Farr M; Scott DGI.
 STUBBS MM, *see* Archer JR.
 STURFIELD G, *see* Nived O.
 STURROCK RD, *see* Belch JF; King SL; Steven MM.
 Sulphasalazine
 active moiety in RA, 215
 and the sulphapyridine derivative, plasma and synovial fluid concentrations, 202
 effect on scavengers of oxygen-derived free radicals in RA, 91
 in RA, 103, Workshop report, 223
 in the treatment of RA: relationship of dose and serum levels to efficacy, 269
 toxicity in patients with RA, 214
 Superoxide anion production, methylation-dependent, 206
 SURRAL K, *see* Bird HA.
 Surveying, the, of the stiffness of articular cartilage across total joint surfaces with reference to the early stages of osteoarthritis, 219
 Susceptibility to and progression of vinyl chloride disease, 96
 SWAN A, *see* Fawthrop FW.
 SWAN AC, SEEDHOM BB. The surveying of the stiffness of articular cartilage across total joint surfaces with reference to the early stages of osteoarthritis (A), 218
 SWANNELL AJ, *see* Al-Hussaini AS.
 SWINBURN WR, *see* Thompson RN.
 SWINSON DR, *see* Thompson RN.
 SYKES B, *see* Wordsworth P.
 SYMMONS DPM, BACON PA, SALMON M, BLANN AD. Lymph nodes—a potential site of lymphocyte activation in RA (A), 198
 SYMMONS DPM, *see also* Salmon M.
 Symptomatic osteoarthritis of the knee: a follow-up study, 40
 Synovial biopsy, value of, 229
 diagnostic, in patients with arthritis of unknown cause, 232
 Synovial cells, human, in inhibition of metalloproteinases, 85
 Synovial debris, rice-bodies and joint lavage, 1
 Synovial dendritic cells, RA, produce IL1 activity, 108
 Synovial fluid
 and plasma
 concentrations of sulphasalazine and the sulphapyridine derivative, 202
 pharmacokinetic comparison of tenoxicam in, 351
 and serum, C-reactive protein in, 203
 comparison of normal and pathological, 61
 human rheumatoid, metalloproteinase inhibitor from, 202
 IgG as antigen for IgM RF, 203
 normal and pathological, 90
 proteoglycans in, effect of intra-articular corticosteroid injections, 221
 Synovial fluids
 from infected joints contain active leucocyte metalloproteinases and no inhibitory activity, 202
 RA, human B-cell colony stimulating activity in, 206
 Synovial inflammation
 and cytidine deaminase, 203
 iron storage and, 79
 Synovial intimal cells, fibronectin production by, 80
 Synovial macrophage dysfunction in RA, 80
 Synovial membrane
 in AS, immunohistological analysis of, 80
 iron deposits and tissue damage in, 210
 RF synthesis by, effect of gold therapy, 103
 rheumatoid,
 granulocytes in, 79
 lymphocyte subsets, effect of drugs on, 216
 morphometric quantitation of, 201
 Synovial membranes, rheumatoid, 74
 Synovial rupture complicating Brucella arthritis, 191
 Synovitis
 knee, 6
 rheumatoid, desferrioxamine treatment for, 214
 Syphilis and SLE, antibody activity in, 75
 System for culture of human trabecular bone and hormone response profiles of derived cells, 99
 Systemic lupus erythematosus
 antibody activity in, 75

GENERAL INDEX

- anticoagulant and lung function, 95
 complement fixation by anti-DNA in, 83
 cross-reacting anti-DNA antibody idiotypes in skin biopsies, 100
 in a District General Hospital, 208
 in an adult population in Southern Sweden, 147
 β_2 -microglobulin binding activity in sera from, 77
 nephritis, lupus-like, heralding, 256
 new antibody, 101
 prevention of immune precipitation in, 82
 psychophysiological determinants of fatigue in, 110
 restricted auto-antibody response to a limited set of cellular antigens, 111
 serum biochemistry in RA, seronegative arthropathies and, 205
- Systemic sclerosis (SS)
 antinuclear antibodies in the families of patients with, 212
 fibrinolytic activity in, 211
 platelet sensitivity, 91
 to a prostacyclin analogue in, 346
 progressive, metabolism of neutrophils in, 211
 the dermal microvasculature in, 211
- TAGGART A, *see* Fay A.
 'Taking the cure'—spa therapy was an effective treatment for lead poisoning and gout, 208
- Technetium methylene diphosphonate isotope, 197
 Tenoxicam in plasma and synovial fluid, 351
 Thalidomide in the treatment of orogenital ulceration, 95
- THE HSG, STEVEN MM, VAN DER LINDEN SM, CATS A.
 Evaluation of diagnostic criteria for AS: a comparison of the Rome, New York and modified New York criteria in patients with positive clinical history screening test for AS, 242
- Thermography in assessment of algodystrophy, 85
 THOMAS DP PAGE, *see* Coughlan RJ.
 THOMPSON D, *see* Howe A.
 THOMPSON J, *see* Fay A.
 THOMPSON PW, JONES DD, CURREY HLF. Cytidine deaminase: a measure of synovial inflammation? (A), 203
 THOMPSON PW, KIRWAN JR, BARNES CG. Practical results of treatment with disease-modifying antirheumatoid drugs, 167
 THOMPSON RN, EDELMAN J, WATTS C, ESDAILE J, RUSSELL AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory RA (A), 101
 THOMPSON RN, WARDMAN P, NEWTON P, STANLEY JK, SWINBURN WR, SMITH P, BURKE M, SWINSON DR. Splinting of ruptured extensor tendons of the fingers in patients with RA (A), 199
 Thrombocytopenia, gold-induced, 204
 TOLFREE S, *see* Snaith ML.
 Topographical variation of proteoglycan synthesis in cartilage of human femoral condyle, 219
 TOTHILL P, *see* Reid DM.
 Toxicity of sulphasalazine in patients with RA, 214
 Trabecular bone, human
 culture of, 99
 cultured, histological study, 98
 Transferrin receptor bearing cells in RA and an *in vitro* model of lymphocyte activation, 217
 Two-dimensional epidemiology (E), 310
- Ulterative colitis, family survey of arthritis in, 208
 URBAN J, *see* Menashi S.
- Urinary monoclonal free light chains, 207
 Use of sequential analysis to assess patient preference for local skin anaesthesia during knee aspiration, 118
- Value of synovial biopsy, 229
 VANDENBERG MJ, *see* Brandman S.
 VAN DER KORST JK, *see* Cuperus RA.
 VAN DER LINDEN SM, *see* The HSG.
 VAN STADEN DA, *see* Brighton SW.
 Vasculopathies, multiple, and hepatitis B in a family, 19
 Vasopressin, antidiuretic effect of, influence of indomethacin, 102
 VENABLES PJW, CHARLES PJ, MAINI RN. SLE—a restricted auto-antibody response to a limited set of cellular antigens? (A), 111
 VENABLES PJW, GRIFFITHS PD, CHARLES PJ, MELSOM RD, MAINI RN. Antibodies to CMV and EBV in PSS and RA (A), 88
 VENABLES PJW, *see also* Horsfall AC; Williams DG.
 VERMEER BJ, *see* De Clerck LS.
 DE VERNEJOUL F, *see* Kajan A.
 Vinyl chloride disease, 96
 VISCHER TL, JEANNET M. Lymphocytotoxic auto-antibodies in RA: relation to HLA-DR2, and titres of R and ANFs (A), 104
 Vitamin C deficiency in RA, 362
- WAALAN K, *see* Duff GW.
 WAINWRIGHT AC, *see* Morris CJ.
 WAKEFIELD D, ROBINSON P, EASTER J, GRAHAM D, PENNY R. Decreased chemiluminescent associated phagocytic response of PBMN to *Chlamydia trachomatis* in patients with HLA-B27+ anterior uveitis, 332
 WALKER DJ, POUND JD, GRIFFITHS ID, POWELL RJ. A family study of RA: the diagnostic value of RF tests (A), 105
 WALKER D MURRAY, *see* O'Sullivan M.
 WALKER P, *see* Irving WL.
 WALTERS MT, CAWLEY MID, MOORE K, SMITH JL. The effect of disease-modifying drugs on rheumatoid synovial membrane lymphocyte subsets (A), 216
 WALTERS MT, CAWLEY MID, STEVENSON FK, HERBERT A, SMITH JL. Lymphoma in Sjögren's syndrome: diagnostic significance of urinary monoclonal free light chains (A), 207
 WALTON KW, *see* Struthers GR.
 WARD DJ, *see* Bernstein RM; Lea DJ.
 WARDMAN P, *see* Thompson RN.
 WATT I, *see* Doherty M; Hutton C.
 WATTS C, *see* Thompson RN.
 WAUGH APW, *see* Nouri AME.
 WEBB C, *see* Sheldon PJ.
 WEBB J, *see* Zoma A.
 WEISS JB, *see* Wiseman DM.
 WELSH KI, *see* Black CM; Emery P; Pereira RS.
 WELTEVREDON EF, *see* De Clerck LS.
 WESTEDT ML, *see* De Clerck LS.
 WEVER R, *see* Cuperus RA.
 WHALEY K, *see* Mitchell WS; Zoma A.
 WHELAN A, *see* Hanly J.
 Which is the active moiety of sulphasalazine in RA? 215
 Which rheumatoid patients show progressive joint damage while receiving slow-acting drugs? 209
 WHICHER JT. The acute-phase proteins (A), 94
 WHICHER JT, *see also* Hutton CW.
 WHITE AG, *see* Binder AI.
 WILBOURN B, *see* Brown KA.

GENERAL INDEX

- WILLEMS WJ, MACFARLANE JD, ROZING PM. Gerard cup arthroplasty in inflammatory arthropathy of the hip (A), 199
- WILLIAMS A, *see* Blake DR.
- WILLIAMS BD, *see* O'Sullivan M.
- WILLIAMS DG, GOTTLIEB E, SMITH PR, STEITZ JA, VENABLE PJW, MAINI RN. The RNA and immunoreactive polypeptide components of La antigen (SS-B) identified using monoclonal antibodies (A), 100
- WILLIAMS ED, *see* Rajan KT.
- WILLIAMS EH, *see* Longstaff J.
- WILLIAMS PL, BJARNASON I, ZANELLI J, CRAWLEY J, ANSELL BM. Ileocaecal inflammation due to NSAIDs: detection by indium-111-labelled leucocyte scans (A), 77
- WILLIAMS TDM, *see* Dixey JJ.
- WILLIAMSON EA, *see* Puttick AH.
- WILLOUGHBY DA, *see* Edwards JCW.
- WILTON M, *see* Gibson T.
- WINYARD P, *see* Brailsford S.
- WISEMAN DM, WEISS JB. Lymphocyte angiogenic factor: fact or fiction (A), 203
- WITHRINGTON RH, GIRGIS FL, SEIFERT MH. A comparative study of the aetiological factors in shoulder pain, 24
- WOJNARUSKA F, *see* Isenberg DA.
- WOLLHEIM F, *see* Nived O.
- WOLLHEIM FA, *see* Saxne T.
- WOO P, *see* Gibson T.
- WOOD PHN, *see* Schlecht BJM.
- WOODROW DF, *see* Kennedy TD.
- WOODS KL, *see* Coppock JS.
- WOODS R, *see* FitzGerald OM.
- WOOLF AD, *see* Maslen C.
- WOOLF CJ. Pain mechanisms: recent advances in the study of the neurobiology of pain (A), 213
- WORDSWORTH P, OGILVIE D, SYKES B, SMITH R. Exclusion of the α_1 (II) collagen gene as the mutant locus in type II Ehlers-Danlos syndrome (A), 111
- WRIGHT JK, CAWSTON TE, NOBLE DP, HAZLEMAN BL. The production of tissue inhibitors of metalloproteinases by human synovial cells *in vitro* (A), 85
- WRIGHT JK, *see also* Crisp AJ; Smith AJ.
- WRIGHT V, *see* Bird HA; Ellis MI; Howe A; Sitton NG.
- X-ray assessment in RA, methods of, 31
- YARKER YE, *see* Aspden RM.
- YATES DAH, *see* Brown KA.
- YOSHINO S, *see* Morris C.
- ZANELLI J, *see* Williams PL.
- ZITMAN FG. Biofeedback, hypnosis and relaxation training in chronic pain (A), 213
- ZOMA A, *see* Pullar T.